Absci Corporation
ABSI | NASDAQ
$9.82
+$0.17 (+1.76%)
At close: Sep 21, 2026, 4:00 PM ET
$9.77
-$0.05 (-0.51%)
Pre-market:
Sep 22, 2026, 4:59 AM ET
Company Profile
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President & Director |
| Shelby Walker | Chief Legal Officer |
| Zachariah Jonasson | Chief Business Officer & Chief Financial Officer |
| Alexander Khan | CVP of Finance & Head of Investor Relations |
| Amer-Denis Akkad | Vice President of Research |
| Christine Lemke | Senior Vice President of Portfolio & Growth Strategy |
| Jeanne Schreuder SPHR | Senior Vice President of People & Experience |
| Moetaz Albizem | Senior Vice President of Clinical Operations |
| Ransi Somaratne FACC | Chief Medical Officer |
| Todd Bedrick | Senior Vice President & Chief Accounting Officer |
| Wen Sha | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 3 | Filing |
| Jul 06, 2026 | 4 | Filing |
| Jun 26, 2026 | 4 | Filing |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 424B5 | Filing |
| Jun 24, 2026 | 8-K | Current Report |
Absci Corporation
| Country | United States |
| IPO Date | Jul 21, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Sean McClain |
Contact Details
18105 SE Mill Plain Boulevard Vancouver,
Washington 98683 United States
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| SIC Code | 8731 |
Recent News
- 1 day ago / defenseworld.netContrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
- 5 days ago / seekingalpha.comAbsci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 14 days ago / seekingalpha.comAbsci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
- 21 days ago / globenewswire.comAbsci to Participate in Upcoming Investor Conferences
- 1 month ago / zacks.com4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
- 1 month ago / seekingalpha.comAbsci Corporation (ABSI) Q2 2026 Earnings Call Transcript
- 1 month ago / marketbeat.comAbsci Q2 Earnings Call Highlights
- 1 month ago / globenewswire.comAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- 1 month ago / 247wallst.comThe Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
- 2 months ago / zacks.comAre Medical Stocks Lagging ABSCI CORP (ABSI) This Year?
Add to Watchlist
Select watchlists to add or remove ABSI